Should I buy or sell Personalis stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Personalis in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" PSNL shares. View PSNL analyst ratings or view top-rated stocks .

What is Personalis' stock price target for 2024?

3 equities research analysts have issued 12 month target prices for Personalis' shares. Their PSNL share price targets range from $2.30 to $7.50. On average, they expect the company's stock price to reach $4.93 in the next year. This suggests a possible upside of 134.9% from the stock's current price. View analysts price targets for PSNL or view top-rated stocks among Wall Street analysts .

How have PSNL shares performed in 2023?

Personalis' stock was trading at $1.98 on January 1st, 2023. Since then, PSNL shares have increased by 6.1% and is now trading at $2.10. View the best growth stocks for 2023 here .

When is Personalis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 22nd 2024. View our PSNL earnings forecast .

How were Personalis' earnings last quarter?

Personalis, Inc. (NASDAQ:PSNL) announced its earnings results on Tuesday, November, 7th. The company reported ($0.51) earnings per share for the quarter, topping the consensus estimate of ($0.54) by $0.03. The company had revenue of $18.25 million for the quarter, compared to analyst estimates of $16.97 million. Personalis had a negative trailing twelve-month return on equity of 58.66% and a negative net margin of 159.91%.

What ETF holds Personalis' stock ?

ARK Genomic Revolution ETF holds 5,920,884 shares of PSNL stock, representing 0.56% of its portfolio.

What is John West's approval rating as Personalis' CEO?

17 employees have rated Personalis Chief Executive Officer John West on Glassdoor.com . John West has an approval rating of 75% among the company's employees.

What other stocks do shareholders of Personalis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Personalis investors own include Enphase Energy (ENPH) , Pfizer (PFE) , Dynavax Technologies (DVAX) , QUALCOMM (QCOM) , Advanced Micro Devices (AMD) , NIO (NIO) , NVIDIA (NVDA) , Viking Therapeutics (VKTX) , AbbVie (ABBV) and

When did Personalis IPO?

(PSNL) raised $100 million in an initial public offering (IPO) on Thursday, June 20th 2019. The company issued 6,700,000 shares at $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen and Company acted as the underwriters for the IPO and Oppenheimer was co-manager.

How do I buy shares of Personalis?

Shares of PSNL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Positive News SentimentPositive News

NASDAQ:PSNL

Personalis (PSNL) Stock Price, News & Analysis

$2.10

-0.25 (-10.64%)

(As of 12/29/2023 ET)

Compare

Today's Range: $1.96
▼
$2.36
50-Day Range: $0.93
▼
$2.35
52-Week Range: $0.89
▼
$4.31

Volume: 1.10 million shs
Average Volume: 588,686 shs
Market Capitalization: $102.96 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $4.93

Personalis MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 134.9% Upside
$4.93 Price Target
Short Interest: Healthy
2.02% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.66
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: Selling Shares
$42,202 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($2.15) to ($1.57) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.51 out of 5 stars

Medical Sector

164th out of 950 stocks

Medical Laboratories Industry

5th out of 20 stocks

3.3

Analyst's Opinion

Consensus Rating
Personalis has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $4.93, Personalis has a forecasted upside of 134.9% from its current price of $2.10.
Amount of Analyst Coverage
Personalis has only been the subject of 1 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
2.02% of the float of Personalis has been sold short.
Short Interest Ratio / Days to Cover
Personalis has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Personalis has recently decreased by 3.53%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Personalis does not currently pay a dividend.
Dividend Growth
Personalis does not have a long track record of dividend growth.

4.2

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Personalis has received a 60.70% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Genomics analysis tools" and "DNA sequencers" products. See details.
Environmental Sustainability
The Environmental Impact score for Personalis is -0.66.

2.7

News and Social Media Coverage

News Sentiment
Personalis has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.84 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Personalis this week, compared to 1 article on an average week.
Search Interest
Only 1 people have searched for PSNL on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Personalis insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $42,202.00 in company stock.
Percentage Held by Insiders
Only 7.50% of the stock of Personalis is held by insiders.
Percentage Held by Institutions
53.76% of the stock of Personalis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Personalis are expected to grow in the coming year, from ($2.15) to ($1.57) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Personalis is -0.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Personalis is -0.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Personalis has a P/B Ratio of 0.44. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Personalis Stock (NASDAQ:PSNL)

Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test to optimize therapy selection and match patients to clinical trials; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities. The company also provides ACE platform for clinical and therapeutic applications, such as neoantigen prediction, biomarker identification, and novel drug target selection. It serves pharmaceutical, biopharmaceutical, diagnostic testing, and biotechnology companies; healthcare providers; universities; non-profits; and government entities. The company was incorporated in 2011 and is headquartered in Fremont, California.

PSNL Stock Price History

30 days | 90 days | 365 days | Advanced Chart

PSNL Stock News Headlines

December 18, 2023 | finance.yahoo.com

Even With A 37% Surge, Cautious Investors Are Not Rewarding Personalis, Inc.'s (NASDAQ:PSNL) Performance Completely

December 4, 2023 | finance.yahoo.com

Personalis Extends Cash Position Into 2026, Provides Update on Key Initiatives

December 31, 2023 | MarketBeat Internal (Ad)

MarketBeat All Access New Year's Sale - Just $1.00

Access our premier research platform that includes MarketBeat Daily Premium, portfolio monitoring tools, stock screeners, research tools, a real-time news feed, email and SMS alerts, the MarketBeat Idea Engine, proprietary brokerage rankings, extended data export tools and much more. Save 75% Your 2024 Subscription. Just $1.00 for the first 30 days.

December 1, 2023 | bizjournals.com

East Bay cancer test company to shed another 65 jobs

December 1, 2023 | msn.com

Cancer test developer Personalis to cut 65 jobs to reduce costs

November 28, 2023 | finance.yahoo.com

Personalis and Tempus Enter into a Strategic Collaboration to Advance Cancer Testing

November 16, 2023 | benzinga.com

Myriad Genetics and Personalis Partner to Market Solutions to Pharma Customers

November 9, 2023 | markets.businessinsider.com

Promising Financial Performance and Product Launch Bolster Buy Rating for Personalis

December 31, 2023 | MarketBeat Internal (Ad)

MarketBeat All Access New Year's Sale - Just $1.00

November 8, 2023 | finance.yahoo.com

Personalis, Inc. (NASDAQ:PSNL) Q3 2023 Earnings Call Transcript

November 7, 2023 | msn.com

Personalis GAAP EPS of -$0.60 misses by $0.08, revenue of $18.2M beats by $1.22M

November 7, 2023 | sfgate.com

Personalis: Q3 Earnings Snapshot

November 7, 2023 | finance.yahoo.com

Personalis Reports Third Quarter 2023 Financial Results

November 6, 2023 | benzinga.com

Earnings Outlook For Personalis

October 27, 2023 | msn.com

Personalis start early access program for cancer detection blood test

October 26, 2023 | finance.yahoo.com

Personalis Launches NeXT Personal® Dx for Early Access Clinical Use in Residual Disease and Recurrence Detection in Cancer

October 24, 2023 | finance.yahoo.com

Personalis to Announce Third Quarter 2023 Financial Results

October 21, 2023 | finance.yahoo.com

Analysis from TRACERx Study Reveals More Sensitive and Earlier ctDNA Detection in Lung Cancer Patients by Personalis' MRD Technology

October 19, 2023 | finance.yahoo.com

Personalis Announces Late-Breaking NeXT Personal Abstract and Proffered Paper Presentation at ESMO 2023

October 18, 2023 | finance.yahoo.com

Personalis Appoints Former Roche Diagnostics and GRAIL Executive Deepshikha Bhandari as SVP, Regulatory, Quality and Clinical Compliance

October 12, 2023 | finance.yahoo.com

Personalis (NASDAQ:PSNL) Will Have To Spend Its Cash Wisely

September 6, 2023 | msn.com

Personalis: Collaborations Should Ignite Growth Narrative

August 29, 2023 | finance.yahoo.com

Personalis to Present at the 21st Annual Morgan Stanley Global Healthcare Conference

August 8, 2023 | finance.yahoo.com

Personalis Reports Second Quarter 2023 Financial Results

July 25, 2023 | finance.yahoo.com

Personalis to Announce Second Quarter 2023 Financial Results

July 13, 2023 | finance.yahoo.com

Personalis (NASDAQ:PSNL) adds US$23m to market cap in the past 7 days, though investors from three years ago are still down 86%

June 26, 2023 | msn.com

Personalis files second IP infringement suit against Foresight Diagnostics

See More Headlines

Receive PSNL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Personalis and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/07/2023
Today: 12/31/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 2/22/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Medical laboratories
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:PSNL
CUSIP: N/A
CIK: 1527753
Web: www.personalis.com
Phone: (650) 752-1300
Fax: N/A
Employees: 395
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $4.93
High Stock Price Target: $7.50
Low Stock Price Target: $2.30
Potential Upside/Downside: +134.9%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.38)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-113,320,000.00
Net Margins: -159.91%
Pretax Margin: -159.79%
Return on Equity: -58.66%
Return on Assets: -41.66%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.56
Quick Ratio: 4.31

Sales & Book Value

Annual Sales: $65.05 million
Price / Sales: 1.58
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.75 per share
Price / Book: 0.44

Miscellaneous

Outstanding Shares: 49,030,000
Free Float: 45,354,000
Market Cap: $102.96 million
Optionable: Not Optionable
Beta: 1.86

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Mr. Christopher M. Hall (Age 54)
President, CEO & Director
Comp: $506.39k
Mr. Aaron L. Tachibana (Age 62)
CFO & COO
Comp: $569.6k
Dr. Richard Chen M.D. (Age 52)
M.S., Executive VP of R&D and Chief Medical Officer
Comp: $584.17k
Dr. Russ B. Altman M.D.
Ph.D., Co-Founder and Member of Clinical & Scientific Advisory Board
Dr. Euan A. Ashley DPHIL (Age 51)
FRCP, M.D., Ph.D., Co-Founder and Member of Clinical & Scientific Advisory Board
Dr. Michael P. Snyder Ph.D.
Co-Founder and Member of Clinical & Scientific Advisory Board
Mr. Stephen M. Moore J.D. (Age 50)
VP, General Counsel & Corporate Secretary
Mr. Michael J Fitzpatrick
Vice President of Worldwide Sales
Ms. Susan Moriconi M.B.A.
VP of People & Chief HR Officer
Dr. Christian Haudenschild Ph.D.
Senior Vice President of Genomic Laboratory Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

PSNL Stock Analysis - Frequently Asked Questions

Should I buy or sell Personalis stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Personalis in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" PSNL shares.
View PSNL analyst ratings or view top-rated stocks.
What is Personalis' stock price target for 2024?: 3 equities research analysts have issued 12 month target prices for Personalis' shares. Their PSNL share price targets range from $2.30 to $7.50. On average, they expect the company's stock price to reach $4.93 in the next year. This suggests a possible upside of 134.9% from the stock's current price.
View analysts price targets for PSNL or view top-rated stocks among Wall Street analysts.
How have PSNL shares performed in 2023?: Personalis' stock was trading at $1.98 on January 1st, 2023. Since then, PSNL shares have increased by 6.1% and is now trading at $2.10.
View the best growth stocks for 2023 here.
When is Personalis' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, February 22nd 2024.
View our PSNL earnings forecast.
How were Personalis' earnings last quarter?: Personalis, Inc. (NASDAQ:PSNL) announced its earnings results on Tuesday, November, 7th. The company reported ($0.51) earnings per share for the quarter, topping the consensus estimate of ($0.54) by $0.03. The company had revenue of $18.25 million for the quarter, compared to analyst estimates of $16.97 million. Personalis had a negative trailing twelve-month return on equity of 58.66% and a negative net margin of 159.91%.
What ETF holds Personalis' stock ?: ARK Genomic Revolution ETF holds 5,920,884 shares of PSNL stock, representing 0.56% of its portfolio.

What is John West's approval rating as Personalis' CEO?: 17 employees have rated Personalis Chief Executive Officer John West on Glassdoor.com. John West has an approval rating of 75% among the company's employees.
What other stocks do shareholders of Personalis own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Personalis investors own include Enphase Energy (ENPH), Pfizer (PFE), Dynavax Technologies (DVAX), QUALCOMM (QCOM), Advanced Micro Devices (AMD), NIO (NIO), NVIDIA (NVDA), Viking Therapeutics (VKTX), AbbVie (ABBV) and
When did Personalis IPO?: (PSNL) raised $100 million in an initial public offering (IPO) on Thursday, June 20th 2019. The company issued 6,700,000 shares at $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen and Company acted as the underwriters for the IPO and Oppenheimer was co-manager.
How do I buy shares of Personalis?: Shares of PSNL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PSNL) was last updated on 12/31/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial